Cancer Family
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
CI-CAN-00000039Explore in graph →
Non-malignant864 active trials6 approved drugs159 evidence items
- NCIt
- C35562
Loading cancer entity…
Cancer Family
CI-CAN-00000039Explore in graph →
Clinical trials
3,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07488754 | Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) | recruiting | N/A | 35 | Medical University of WarsawOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511725 | Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma(PRISM) | recruiting | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 6, 2026 |
| clinicaltrials |
| NCT05789394 | Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07417761 | Tuvusertib in Astrocytoma With ATRX Mutation(TUVASTRAT) | recruiting | Phase 2 | 56 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07506239 | Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma | recruiting | N/A | 40 | University of California, San FranciscoOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | recruiting | Phase 1 / Phase 2 | 62 | David Baskin MDOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03603405 | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | recruiting | Phase 1 / Phase 2 | 62 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04559230 | Sacituzumab Govitecan in Recurrent Glioblastoma | recruiting | Phase 2 | 32 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05702749 | Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas(VS PREHAB) | recruiting | N/A | 36 | Medical College of WisconsinOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06482905 | Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | recruiting | Phase 1 | 52 | Tcelltech Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06725173 | Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis. | recruiting | — | 100 | University of WashingtonOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480941 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma(DUAL-CAR-NK-GB) | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04943848 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | recruiting | Phase 1 | 36 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476794 | Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma(TEMPO) | recruiting | Phase 2 | 118 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06504381 | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | recruiting | Phase 1 / Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07461948 | Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients | recruiting | Phase 3 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03141021 | Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors | recruiting | — | 1,050 | Washington University School of MedicineOTHER | 5 | Mar 9, 2026 | clinicaltrials |
| NCT05859659 | Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE) | recruiting | — | 70,000 | Yaou LiuOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07459101 | UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4(UNITED-4) | recruiting | N/A | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06917885 | CUE-102 in Recurrent Glioblastoma | recruiting | Phase 1 | 18 | David Reardon, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04908709 | Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors | recruiting | N/A | 25 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06546631 | Investigating Mechanistic Predictors of Interpatient Variability and Temozolomide (TMZ) Induced Haematological Toxicity for Glioma Patients(Improve TMZ) | recruiting | — | 55 | University College CorkOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07447531 | T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas | recruiting | N/A | 15 | John M. BuattiOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04425434 | Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma(GFARB12019) | recruiting | — | 3,000 | French Africa Pediatric Oncology GroupOTHER | 6 | Mar 2, 2026 | clinicaltrials |
| NCT06719440 | Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume(BELGICA) | recruiting | N/A | 347 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07236840 | Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors(NEMO) | recruiting | — | 600 | Tata Memorial CentreOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07405372 | Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas | recruiting | — | 10 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06058988 | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07426848 | OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients(OTSMILE) | recruiting | N/A | 96 | Royal College of Surgeons, IrelandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05345002 | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | recruiting | Phase 2 | 55 | Stephen Bagley, MD, MSCEOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07318818 | A Clinical Trial of P134 Cells in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 26 | Tasly Pharmaceutical Group Co., LtdINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04278118 | Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study(HiPPI) | recruiting | N/A | 70 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04765514 | Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients | recruiting | Phase 2 | 107 | AHS Cancer Control AlbertaOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06222138 | Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma(EXOFIELDS) | recruiting | N/A | 80 | Institut Claudius RegaudOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07263438 | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial(Phenix) | recruiting | Phase 2 | 59 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06132685 | Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial | recruiting | Phase 2 | 200 | Emory UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05139277 | Evaluation of the CONVIVO System | recruiting | N/A | 30 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04872543 | A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | recruiting | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06650163 | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07391215 | 5G-PEARL: Paxalisib in Malignant Brain Tumours(5G-PEARL) | recruiting | Phase 1 / Phase 2 | 64 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05653622 | Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma(SIB-DOPA) | recruiting | Phase 2 | 75 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05653635 | Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study(ReciDOPA) | recruiting | Phase 2 | 54 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05756985 | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue | recruiting | — | 120 | Baptist Health South FloridaOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05331521 | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).(ImproveCodel) | recruiting | Phase 3 | 406 | University Hospital HeidelbergOTHER | 1 | Feb 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2026source: clinicaltrials